IP Library Granted Patent US 8,865,171
Granted Patent B2
US 8,865,171 · App. 11/629,682 · Granted Oct 21, 2014

Soluble forms of Hendra and Nipah virus G glycoprotein

Inventors: Christopher C. Broder (Silver Spring, MD); Katharine N. Bossart (San Francisco, CA)
Assignee: The Henry M. Jackson Foundation For the Advancement of Military Medicine, Inc.
C07K14/115G01N33/56983C07K16/1027C07K14/005A61K2039/505C12N2760/18222G01N33/6854A61K39/00C07K14/07
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,865,171
App. No.
11/629,682
Granted
Oct 21, 2014
Kind
B2
Abstract

This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.

Claims (9)

1. An isolated oligomeric peptide wherein the monomers of the oligomeric peptide consist of the ectodomain of the Hendra virus G protein with an amino acid sequence of SEQ ID NO: 16.

2. The isolated oligomeric peptide of claim 1 , which retains one or more characteristics of a native Hendra virus G protein.

3. The isolated oligomeric peptide of claim 2 , wherein the one or more characteristics are selected from the group consisting of ability to interact with a viral host receptor cell, ability to elicit an antibody reaction, ability to elicit a neutralizing antibody reaction, ability to block or prevent infection of a host cell by Hendra virus, and combinations thereof.

4. The isolated oligomeric peptide of claim 1 , wherein the oligomeric peptide is a dimer.

5. A pharmaceutical composition comprising the isolated oligomeric peptide of claim 4 and a pharmaceutically acceptable carrier.

6. The isolated oligomeric peptide of claim 1 , wherein the oligomeric peptide is a tetramer.

7. A pharmaceutical composition comprising the isolated oligomeric peptide of claim 1 and a pharmaceutically acceptable carrier.

8. A fusion protein containing the oligomeric peptide of claim 1 linked to another peptide.

9. The fusion protein of claim 8 , wherein the another peptide is derived from vaccinia virus.

Assignments (4)
CONFIRMATORY LICENSE Recorded Oct 3, 2016
From: HENRY M. JACKSON FDN FOR THE ADV MIL/MED
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039920/0824 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2014
From: BRODER, CHRISTOPHER
To: UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES
Reel/Frame 033434/0544 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2014
From: BOSSART, KATHARINE
To: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
Reel/Frame 033434/0553 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2014
From: UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES
To: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
Reel/Frame 033434/0564 →
Continuity (1)
Related Publication 20090041772A1 · Feb 12, 2009